Drug intelligence / Profile preview

Levomekol

Development stage
Unknown
Lead developer
Nizhpharm
Modality
Small Molecules
Administration
Topical
01

Overview

Levomekol is a topical combination ointment manufactured by Viola Pharmaceutica Fabrika. It contains two active ingredients: chloramphenicol (levomycetin), a broad-spectrum antibiotic, and methyluracil, a tissue regeneration stimulant. Chloramphenicol exerts its antimicrobial effect by binding to the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis in a wide range of gram-positive and gram-negative bacteria, including staphylococci and *E. coli*. Methyluracil promotes wound healing by stimulating cellular regeneration and nucleic acid metabolism. The ointment is primarily indicated for the treatment of purulent wounds in the first phase of the wound process, as well as boils, trophic ulcers, and infected burns. It exhibits combined antimicrobial, anti-inflammatory, and reparative actions.

Brand names
Levomekol
Other names
Levomekol-Viola
02

Targets

PTC (50S ribosomal peptidyl transferase center)CYP2C19 (Cytochrome P450 2C19)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on Levomekol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Levomekol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call